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Background: Clinicians often encounter information about drug-drug interactions (DDIs) during clinical practice.
This information is found within product information (hardcopy and electronic) and various electronic systems.
Prescribers may receive medication-related communications in practice that are distributed by facsimile (fax), mail,
or telephone from pharmacies and pharmacy benefit managers (PBMs). The purpose of this study was to determine
if near-real time fax alerts for potential drug-drug interactions (PDDIs) would influence prescribing.
Methods: A prospective study, in cooperation with a pharmacy benefit manager (PBM), was conducted targeting
18 clinically important PDDIs. Fax alerts included an individualized letter to the prescriber with a list of the
interacting drugs, PDDI evidence summaries with citations, and recommended clinical management strategies.
Among the 18 PDDIs, 13 PDDIs could be assessed for prescription therapy changes using pharmacy claims data. A
prospective cohort design was used to evaluate changes in prescription dispensing 90-days following a PDDI fax
alert.
Results: A total of 8,075 fax alerts were sent to prescribers and there were 4,712 alerts for the 13 PDDIs that could
be assessed for change using pharmacy claims data. There were 2,019 patients (interventions) for which fax alerts
were sent to their prescribers who were matched with a control group consisting of patients with the same PDDIs
but for whom no fax alert was sent. Overall, this study found 154 (7.6%) of patients in the fax alert group compared
to 132 (6.5%) in the control group had changes in therapy (p = 0.177).
Conclusions: This fax alert intervention program observed no statistically significant differences in prescribing with
a fax alert compared to the control group. If PBMs chose to send individualized, evidence-based information to
clinicians regarding drug-drug interactions, this study suggests it may not be an effective intervention to mitigate
harm.
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Interventions to reduce harm associated with drug-drug
interactions (DDIs) are commonly encountered by pre-
scribers in everyday practice. These interventions are
among many other medication-related communications
directed to prescribers, including messages sent by fac-
simile (fax), mail, or telephone from pharmacies and
pharmacy benefit managers (PBMs). Providers with
electronic health records and/or electronic prescribing
(e-prescribing) also are presented medication-related
messages and alerts as a part of their systems’ clinical* Correspondence: armstrong@pharmacy.arizona.edu
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distribution, and reproduction in any mediumdecision support. Because clinicians receive many alerts
from a variety of sources, it is imperative to use only the
most effective interventions aimed to improve patient
safety related to DDIs.
PBMs are in a unique position to identify the co-
prescribing of medications known to interact (i.e., poten-
tial drug-drug interactions or PDDIs) because they
process and capture data on a large proportion of pre-
scription claims in the United States [1]. PDDIs are
detected through retrospective drug utilization review
(DUR) programs that are conducted shortly after medi-
cations are dispensed to screen prescription claims data
for patient exposure to specific DDIs. Letters may be
sent to prescribers by fax or by mail to increasetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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change in therapy or increased monitoring [2]. However,
some DUR programs have been implemented without
satisfactory evidence to support the selected screening
criteria or the effect of the interventions on prescribing
patterns or patient outcomes [1-3]. To the authors’
knowledge, studies evaluating the effects of PDDI fax
alerts on prescribing have not been published.
This study was planned and conducted in association
with a PBM company (MedImpact Healthcare Systems,
Inc.) to assess the impact of a fax alert program focused
on select PDDIs. The purpose of this study was to meas-
ure the change in pharmacy claims after sending a fax
alert to prescribers as compared to a control group that
did not receive a fax alert. The study also evaluated pre-
scribers’ opinions about the fax alert method but those
results are reported elsewhere [4].
Methods
This was a prospective cohort design study conducted to
identify patients exposed to 18 PDDIs and to distribute
evidence-based information and suggested actions (e.g.,
change drug, modify dosing or administration, monitor-
ing, and/or patient education). Among the 18 PDDIs, 13
PDDIs could be assessed for prescription therapy
changes using pharmacy claims data. Clinical informa-
tion on the mechanism of action, potential severity of
the interaction, recommended alternative medications
and management strategies, and supporting references
and documentation were included in the alert. The alerts
were faxed the following morning (i.e., near-real time) to
the prescriber of the second drug of the PDDI. A
matched comparison (control) group, serving as a con-
trol where no fax alerts were sent, was selected from pa-
tients who were exposed to the same PDDIs identified
using pharmacy claims from different health plans man-
aged by the PBM. Changes in medication therapy for the
13 PDDIs were observed and compared among the
intervention and control groups. A “successful change”
was defined as initiation of a recommended therapeutic
alternative within 90 days of the fax alert for the 13
PDDIs. The project was approved by the University of
Arizona Human Subjects Protection Program.
Interacting drugs combinations
Eighteen drug interactions considered to be clinically
important were initially selected for the fax alerts by
consensus among the authors (Table 1). These interac-
tions were selected based on previous research [5]. The
interactions of interest were refined based on input from
the PBM, including a review of the potential clinical
consequences and frequency of co-prescription [6]. An
evidence-based summary was developed for each PDDI
following a review of peer-reviewed publications,product labeling, drug compendia, and reputable online
resources [7-12]. The most appropriate therapeutic op-
tions to minimize the risk of adverse reactions also were
identified using primary (original research), secondary
(databases of articles such as PubMed or Embase), and
tertiary (review articles and book chapters) sources.
Management options included in the alerts were: 1) con-
tinue treatment with patient education and follow-up, 2)
modify the dose or frequency of administration, 3)
monitor pharmacokinetic or pharmacodynamic parame-
ters, 4) change to a therapeutic alternative that is less-
likely to interact, or 5) temporarily hold, or discontinue
therapy. However, claims analysis was not used to deter-
mine the potential impact of certain recommendations
such as therapeutic drug monitoring, changing a dose or
frequency, temporarily holding a medication, educating
the patient, or asking the patient to monitor for certain
signs or symptoms. Five of the 18 PDDIs (amiodarone-
sotalol, ergotamines-triptans, nitrates-phosphodiesterase
type 5 inhibitors, warfarin-amiodarone, and warfarin-
thyroid) were sent for educational purposes to increase
prescriber awareness, but were not evaluated for changes
in prescribing. These five were considered to be clinic-
ally important PDDIs, but they could be managed by
temporarily withholding a dose or through patient edu-
cation to monitor for possible adverse events. These
management strategies would not be detected by exam-
ining data submitted by pharmacies. Thus, a total of 13
PDDIs were included in this analysis (Table 1).
Data source
Two health plans participated in the study. One health
plan was a large managed care organization and the
other was a subset of a managed Medicaid health plan
with approximately 500,000 and 20,000 covered lives, re-
spectively. The PBM performed nightly scans of the
plans’ pharmacy claims for detection of the select PDDIs
and triggered a fax alert to the prescriber of the second
interacting medication. The fax included a letter to the
prescriber introducing the study, the patient’s name, a
list of the interacting medications, and an evidence-
based summary of the literature supporting the inter-
action. The managed care organization implemented the
fax alert program for all 18 of the PDDIs. However, the
Medicaid managed care plan did not implement alerts
for the benzodiazepine-azole PDDI because of state
regulatory concerns about behavioral health medications.
The PDDI screening was based on specific medications
and, therefore, individual prescribers received multiple
fax alerts if they prescribed the same PDDI to multiple
patients. In addition, if a single patient had more than
one PDDI, the prescriber received additional fax alerts
to address each PDDI. Prescriber specialties were identi-
fied for prescribers who received a fax alert based on
Table 1 Potential drug-drug interactions (PDDIs) and suggested therapeutic management strategies included in fax
alert intervention program
PDDIs Suggested therapeutic management strategies
Amiodarone +Macrolides (amiodarone + clarithromycin,
erythromycin or azithromycin)
• Change antibiotic therapy: Change to non-macrolide or non-quinolone
antibiotic
OR
• Monitor: Monitor ECG at baseline and periodically for QTc prolongation; educate
patient about signs of symptomatic cardiac arrhythmias
Amiodarone + Quinolones (amiodarone + gemifloxacin,
levofloxacin, moxifloxacin, or ofloxacin)
• Change antibiotic therapy: Change to ciprofloxacin, penicillins, cephalosporins;
avoid changing to a macrolide (QTc prolongation)
OR
• Monitor: Monitor ECG at baseline and periodically for QTc prolongation; educate
patient about signs of symptomatic cardiac arrhythmias
Benzodiazepines + Azole Antifungal Agents (alprazolam,
midazolam, or triazolam + itraconazole, ketoconazole,
fluconazole, posaconazole, or voriconazole)
• Change benzodiazepine therapy: Change to lorazepam, oxazepam, or
temazepam
OR
• Change antifungal therapy: Change to terbinafine
OR
Monitor: Monitor for excessive sedation and prolonged hypnotic effects; counsel
patients about these possible adverse effects; benzodiazepine dose reduction
may be required
Carbamazepine +Macrolides (carbamazepine +
erythromycin or clarithromycin)
• Change antibiotic therapy: Change to azithromycin or a non-macrolide
antibiotic, such as 2nd/3rd generation cephalosporins, penicillins
OR
• Monitor: Monitor for changes in carbamazepine concentrations
Ciprofloxacin + Tizanidine • Change antibiotic therapy: Change to alternative quinolone (e.g., gemifloxacin,
levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin) or non-quinolone
antibiotic
OR
• Monitor: Monitor for evidence of tizanidine toxicity such as hypotension and
excessive CNS depression
Isotretinoin + Tetracycline or Minocycline Change antibiotic therapy: Change to a non-tetracycline antibiotic (e.g.,
macrolide, amoxicillin, sulfamethoxazole/ trimethoprim)
OR
• Monitor: Monitor and educate patient about signs and symptoms of
pseudotumor cerebri (e.g., papilledema, headache, nausea, vomiting, visual
disturbances)
Simvastatin + Amiodarone • Change statin therapy: Change to fluvastatin, pravastatin, or rosuvastatin
OR
• Monitor: Monitor for unexplained muscle pain, tenderness, or weakness
Statin + Azole Antifungal Agents (atorvastatin, lovastatin,
or simvastatin + itraconazole, ketoconazole, posaconazole,
voriconazole, or fluconazole)
• Change statin therapy: Change atorvastatin, lovastatin, or simvastatin (when
used in combination with itraconazole, ketoconazole, posaconazole, voriconazole,
or fluconazole) to pravastatin OR change fluvastatin or rosuvastatin (when used in
combination with fluconazole or voriconazole) to pravastatin, atorvastatin,
lovastatin, or simvastatin
OR
• Modify: Temporarily stop the statin for short-term azole antifungal therapy or
reduce the statin dosage
OR
• Monitor: Monitor for myopathy and possible rhabdomyolysis
Statins +Macrolides (atorvastatin, lovastatin, or
simvastatin + erythromycin or clarithromycin)
• Change antibiotic therapy: Change to azithromycin or a non-macrolide
antibiotic
OR
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Table 1 Potential drug-drug interactions (PDDIs) and suggested therapeutic management strategies included in fax
alert intervention program (Continued)
• Change statin therapy: Change to fluvastatin, pravastatin, or rosuvastatin
OR
• Temporarily stop the statin for short-term macrolide therapy
OR
• Monitor for signs of myopathy and possible rhabdomyolysis
Theophylline + Quinolones (theophylline + ciprofloxacin
or norfloxacin)
• Change antibiotic therapy: Change to alternative quinolone (e.g., gemifloxacin,
levofloxacin, lomefloxacin, moxifloxacin, ofloxacin) or non-quinolone antibiotic
OR
• Monitor: Monitor for changes in theophylline concentrations
Warfarin + Azole Antifungal Agents (warfarin +
fluconazole, miconazole, or voriconazole)
• Change the antifungal agent: Change to itraconazole, ketoconazole,
posaconazole, or terbinafine
OR
• Monitor: Monitor INR and for bleeding
Warfarin + Fibrates (warfarin + fenofibrate or gemfibrozil) • Change lipid-lowering therapy: Change to pravastatin, fluvastatin, or possibly
extended-release niacin or ezetimibe
OR
• Monitor: Monitor the INR and adjust the warfarin dosage as necessary
Warfarin + Statins (warfarin + fluvastatin, lovastatin,
rosuvastatin, or simvastatin)
• Change statin therapy: Change to atorvastatin or pravastatin
OR
• Monitor: Monitor INR and for bleeding
CNS = central nervous system; ECG = electrocardiogram; INR = International Normalized Ratio.
Armstrong et al. BMC Medical Informatics and Decision Making 2013, 13:32 Page 4 of 9
http://www.biomedcentral.com/1472-6947/13/32Health Market Science data (updated January 2011)
containing self-reported specialties. Because a practi-
tioner may have multiple specialties, only the primary
specialty listed was used for analysis.
The fax alert program was implemented for six
months from May 2010 to November 2010. The control
group consisted of patients for whom a PDDI also was
identified by the same drug criteria but prescribers for
these patients did not receive a fax alert. Control group
patients were matched by PDDI type, although the drugs
may have different active ingredients or formulations. A
1:1 case-control matching process was performed for
each PDDI. Matching was based on age (± 2 years), gen-
der, line of business (i.e., commercial managed care or
managed Medicaid health plan) and time period the
PDDI was detected. Usual pharmacist and physician in-
teractions were allowed to occur without interference.
Thirteen patient cohorts were constructed, one for each
PDDI pair, and analyzed for changes in therapy. A pa-
tient could have been included in more than one cohort
if the patient had multiple PDDIs. However, in the con-
trol group, a patient could only be matched to a single
cohort even if they had multiple PDDIs.
The authors collectively determined the most appro-
priate management action based on available therapeutic
alternatives that would be successful in limiting harm.
Analysis of pharmacy claims was used to identify
changes in therapy corresponding to recommendationsprovided in fax alerts for alternative therapies (see
Table 1). New drug therapies, specified a priori as thera-
peutic alternatives that were filled within 90 days of
when the fax alert was sent were defined as “successful
changes” for the 13 of 18 PDDIs that could be evaluated.
Fax alert counts and changes in therapy were quanti-
fied for each PDDI pair. Chi square tests were conducted
to determine if the proportion of successful therapy
changes were significantly different between fax alert
intervention and control groups. If the sample sizes were
small (< 5 per group), a Fischer exact test was performed.
A logistic regression model was created to assess the im-
pact of variables that may influence a successful therapy
change. The independent variable of interest was the fax
alert intervention compared to the control group. Adjust-
ment variables included: physician characteristics (spe-
cialty, type of health care practitioner), acute medication
(i.e., drugs not considered as maintenance drugs by First
DataBank that are commonly used for short term treat-
ment), First DataBank drug interaction severity level, pa-
tient gender, patient age, and risk category of medication.
RxRisk is a risk stratification model based on pharmacy
claims data and was used as a proxy to identify disease
comorbidities [13].
Results
Of the total of 8,075 fax alerts distributed for all 18
PDDIs, 7,101 were sent for patients with at least 90 days
Table 2 Patient demographics for intervention group
Aggregated Client A Client B
N % N % N %
Age
<18 13 0.2 13 0.2
18 to 39 135 1.9 67 1.1 68 9.3
40 to 64 2004 28.2 1368 21.5 636 87.1
> = 65 4949 69.7 4923 77.3 26 3.6
Gender
Female 3813 53.7 3413 53.6 400 54.8
Male 3288 46.3 2958 46.4 330 45.2
LOB
Commercial 6371 89.7 6371 100
Medicaid 730 10.3 730 100
Total Fax Alerts 7101 100 6371 100 730 100
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4,712 fax alerts sent for the 13 PDDIs evaluated for a
change in prescribing, 2,019 could be successfully
matched with a control.
Slightly greater than two-thirds of the patients (69.7%)
with PDDIs were at least 65 years of age. Women repre-
sented 53.7% of PDDIs. The commercial managed care
plan had 6,371 of 7,101 (89.7%) matched interventions.Table 3 Counts of unique fax alerts sent and recommended t






Warfarin + Statinsa 939 46.5%
Statins + Azolesb 247 12.2%
Warfarin + Fibratesc 303 15.0%
Simvastatin + Amiodarone 169 8.4%
Statins + Macrolidesd 140 6.9%
Benzodiazepines + Azolese 86 4.3%
Warfarin + Azolese 62 3.1%
Ciprofloxacin + Tizanidine 24 1.2%
Isotretinoin + Tetracycline/Minocycline 15 0.7%
Amiodarone + Macrolidesf 11 0.5%
Theophylline + Quinolonesg 12 0.6%
Amiodarone + Quinolonesh 7 0.3%
Carbamazepine + Macrolidesi 4 0.2%
Total 2019 100.0%
NA = not applicable to calculate recommended therapy modification using a pharm
a warfarin + atorvastatin, lovastatin, or simvastatin.
b atorvastatin, lovastatin, or simvastatin + itraconazole, ketoconazole, posaconazole,
c warfarin + fenofibrate or gemfibrozil.
d atorvastatin, lovastatin, or simvastatin + erythromycin or clarithromycin.
e warfarin + fluconazole, miconazole, or voriconazole.
f amiodarone + clarithromycin or erythromycin.
g theophylline + ciprofloxacin or norfloxacin.
h amiodarone + gemifloxacin, levofloxacin, moxifloxacin, or ofloxacin.
i carbamazepine + erythromycin or clarithromycin.Physicians received 7,043 of 8,075 (87.2%) fax alerts sent
and other health professionals received the balance of
fax alerts. Prescribers categorized as primary care practi-
tioners (defined as having a primary specialty of internal
medicine, general practice, or family practice) received
3,764 of 8,075 (46.6%) fax alerts. The demographic char-
acteristics of patients are summarized in Table 2.
Comparison of “successful” changes between the fax
alert intervention and control group are summarized in
Table 3. For the 2,019 PDDI fax alerts matched to a con-
trol group, 154 (7.6%) patients had therapy changed in
the fax alert group compared to 132 (6.5%) in the con-
trol group (p = 0.177). There was wide variation in the
prescribing changes after the fax alert between the 13
different PDDIs. For example, in the statin-macrolide
PDDI, there were 41 of 140 (29.3%) therapy changes
after the fax alert compared to 42 of 140 (30.0%)
changes in the control group (p = 0.89). For the
warfarin-fibrate PDDI, there were 55 of 303 (18.2%)
changes after the fax alert compared to 48 of 303
(15.8%) changes in the control group (p = 0.45). With
the theophylline-quinolones PDDI, there were eight of
12 (66.7%) changes after the fax alert compared to two
of 12 (16.7%) changes in the control group (p = 0.04).
As noted in Table 1, the recommended management
strategy for the benzodiazepine-azole PDDI was to either










9 1.0% 10 1.1% 0.82
2 0.8% 2 0.8% 1.0
55 18.2% 48 15.8% 0.45
8 4.7% 3 1.8% 0.13
41 29.3% 42 30.0% 0.89
9 10.5% 4 4.7% 0.15
1 1.6% 1 1.6% 1.0
13 54.2% 11 45.8% 0.56
1 6.7% 1 6.7% 1.0
2 18.2% 4 36.4% 0.63
8 66.7% 2 16.7% 0.04
3 42.9% 2 28.6% 1.0
2 50.0% 2 50.0% 1.0
154 7.6% 132 6.5% 0.177
acy claims database; PDE5 = phosphodiesterase type 5.
voriconazole, or fluconazole.
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terbinafine. There were eight patients where a change to
lorazepam was noted, two changed to temazepam, and
one changed to terbinafine. These therapy changes were
consistent with the recommended management strategy
suggested in the clinical information contained within
the fax alert.
For the warfarin-fibrate PDDI, the suggested manage-
ment strategy was to change therapy to pravastatin,
fluvastatin, extended-release niacin, or ezetimibe and
monitor the international normalized ratio (INR). There
were 30 patients changed to ezetimibe with or without
simvastatin, 28 patients were changed to pravastatin, 18
were changed to extended-release niacin, and 2 changed
to fluvastatin. These therapy changes also were consist-
ent with the recommended management strategy sug-
gested in the fax alert.
For the ciprofloxacin-tizanidine PDDI, the preferred
management strategy was to change the antibiotic to an
alternative quinolone (e.g., gemifloxacin, levofloxacin,
norfloxacin) or use a non-quinolone antibiotic. There
were four patients where a change to levofloxacin was
observed, three patients were changed to amoxicillin
clavulanate, three were changed to cephalexin, two were
changed to azithromycin, one was changed to amoxicil-
lin, and one was changed to doxycycline.
For the simvastatin-amiodarone PDDI, the suggested
management strategy was to change the statin to
fluvastatin, pravastatin, or rosuvastatin. There were 10
patients that changed to pravastatin and one patient
changed to rosuvastatin, as recommended by the fax
alert.
For the warfarin-statin PDDI, the suggested manage-
ment strategy was to change the statin to atorvastatin or
pravastatin. There were 27 patients where the therapy
was changed to pravastatin and eight where treatment
was changed to atorvastatin.
The logistic regression analysis examined the relation-
ship between successfully changing to a recommended
therapy between the fax alert intervention group and the
control group, adjusting for variables including pre-
scriber characteristics, patient characteristics, and DDI
characteristics (Table 4). The odds ratio of changes in
therapy after the fax alert intervention was not found to
be statistically different from the control group (p =
0.229).
Discussion
This was a prospective cohort design study that assessed
changes in prescribing after sending patient-specific,
evidence-based information about PDDIs with recom-
mended management strategies to prescribers via fax.
Overall, change in treatment was demonstrated in the
pharmacy claims within 90 days of sending the fax alertpackets in 7.6% of patients in the fax alert group. The
only significant finding was that for prescribers who re-
ceived the fax alert for theophylline-quinolones PDDIs,
patients were more likely to have a pharmacy claim
within 90 days for a non-interacting alternative than
those patients in the control group. As measured, there
was no evidence within pharmacy claims that the inter-
vention had an effect on the use of alternative therapies
for any of the other PDDIs. There are several possible
explanations for these findings. First, prescribers may
have already been aware of these PDDIs and had taken
their potential risk into account. They also may have
made changes in therapy that differed from those sug-
gested in the fax alert packet and these prescribing
changes were therefore not detected. Since new expos-
ure to PDDIs was not specifically targeted, patients may
have previously been exposed to and tolerated the medi-
cation combination prior to the prescriber receiving the
alert. Moreover, prescribers may not have perceived the
evidence-based review as compelling enough to change
treatment. Using pharmacy claims data to measure the
effect of the program may not fully account for the true
program effect. Physicians, after receiving these alerts,
may have limited prescribing of future PDDIs, thereby
leading to a potential sentinel effect. Lastly, prescribers
may not have reviewed the fax alert; for instance, the fax
may have been intercepted by office staff and discarded.
Unlike DDI alerts in e-prescribing, there is no way to
determine what proportion of fax alerts were received
and reviewed by prescribers.
The PDDIs for this fax alert intervention were selected
based on the potential clinical consequences, frequency
of co-prescription, and the scientific evidence supporting
the interactions. Unfortunately, the evidence for DDIs is
generally lacking, making “evidence-based” recommen-
dations a challenge [14]. The majority of DDI studies
consist of case reports and premarketing studies evaluat-
ing nonclinical endpoints in healthy subjects. Research
also has shown inconsistencies in DDI listings and sever-
ity ratings among various information sources [15-17].
In hindsight, other PDDIs might have been more appro-
priate for targeted intervention to observe significant
changes in prescribing. For example, the large number
of warfarin PDDIs may have been managed within
anticoagulation clinics. However, an up-to-date list of high-
priority DDIs for alerting is a moving target and requires
careful selection, validation, and ongoing evaluation.
Retrospective DUR programs that communicate drug-
related problems to prescribers by fax or mail are com-
mon in managed care and some studies indicate these
interventions may change prescribing behavior [18-24].
For example, Starner et al reported that nearly half of
potentially inappropriate prescription medications in
older adults were discontinued within six months of a
Table 4 Logistic regression model for whether a patient’s PDDI resulted in a change in medication therapy
Independent variable Coefficient P-value Odds ratio Odds ratio lower 95% Odds ratio upper 95%
Intercept -1.9049 <.0001
Intervention group 0.1706 0.229 1.186 0.898 1.566
Specialist -0.1179 0.4246 0.889 0.666 1.187
Practitioner Type
Nurse Practitioner 0.0993 0.7384 1.104 0.617 1.978
Physician’s assistant -0.726 0.0729 0.484 0.219 1.07
Other Professional -0.6397 0.3211 0.527 0.149 1.866
Physician (Reference)
Acute Medication 0.1962 0.3247 1.217 0.823 1.798
FDB* Severity Level
1-major 0.4161 0.141 1.516 0.871 2.638
2-moderate (Reference)
3-minor -2.7735 <.0001 0.062 0.044 0.089
Male Patient 0.3722 0.0137 1.451 1.079 1.951
Patient’s Age Group
0 - 49 0.1565 0.5175 1.169 0.728 1.878
50 - 64 0.0455 0.7896 1.047 0.749 1.462
65 - 79 (Reference)
80 and Up 0.0877 0.6948 1.092 0.705 1.691
Patient’s RxRisk Categories [13]
Anxiety & Tension 0.3507 0.0343 1.42 1.026 1.965
Asthma 0.3336 0.2724 1.396 0.769 2.533
Cardiac Disease 0.2865 0.1145 1.332 0.933 1.901
Coronary/ Peripheral Vascular disease -0.5916 0.0015 0.553 0.384 0.798
Depression 0.4939 0.0011 1.639 1.217 2.207
Diabetes -0.107 0.4921 0.898 0.662 1.219
Epilepsy 0.0764 0.6746 1.079 0.755 1.542
End stage renal disease 0.0499 0.7402 1.051 0.783 1.412
Glaucoma -0.2878 0.4534 0.75 0.353 1.591
Heart Disease/ Hypertension -0.1678 0.2887 0.846 0.62 1.153
Hyperlipidemia 0.3231 0.1391 1.381 0.9 2.12
Irritable Bowel Syndrome 0.0359 0.8678 1.037 0.68 1.581
*First DataBank.
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packet mailed to prescribers of one or more drugs to
avoid in the elderly [24]. In contrast, Bambauer et al.
found that fax alerts to prescribers about possible
nonadherence among patients with late refills for antide-
pressants did not improve refill rates over two years after
the fax intervention [25]. The authors suggested that
faxed feedback should be carefully evaluated before
widespread use because when used alone, it was inad-
equate. Unlike the present study, few studies that evalu-
ate the effects of retrospective DUR incorporate a
control group [18,23].The role of faxes has also been evaluated in other
health care interventions. Rosewell et al. studied physi-
cians that had received a fax regarding a measles out-
break and noted that recipients were more likely to be
aware of the measles epidemic [26]. The respondents in-
dicated the measles fax alert was useful. Chen et al.
conducted a blinded, randomized, controlled trial that
examined the effectiveness of delivering computer-
generated discharge summaries to general practitioners
by email, fax, mail, or patient hand delivery [27]. Receipt
of the discharge summary was similar with email and
fax, and both of these were significantly higher than mail
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was the preferred method.
At first glance, drug safety notifications alerting pre-
scribers makes intuitive sense. However, Weingart et al.
estimated that a small proportion (10%) of automated
drug safety alerts likely accounted for preventing the ma-
jority (60%) of the adverse drug events [28]. Studies report
high rates (>90%) of alert override in e-prescribing systems
and overall dissatisfaction with drug safety alerts [29-31].
One survey of physicians found that respondents were
generally unsatisfied with DDI and allergy alerts, based on
issues such as outdated information, failure to account for
appropriate drug combinations, and excessive alert vol-
ume [31]. Peng et al. noted that the incidence of poten-
tially serious DDIs was less than 1% of prescriptions in
ambulatory patients [20]. They encouraged the use of add-
itional “automated filters” when screening pharmacy
claims for PDDIs with “additional pharmacist review” [20].
Challenges of retrospective DUR programs include
questionable clinical relevance of certain DDIs, poor evi-
dence for many interactions, inconsistencies among
knowledge bases and compendia, and incomplete patient
data. Those managing and using DUR should consider
criteria that screen for significant preventable problems
[32]. Criteria should include PDDIs with potentially se-
vere medical consequences if action is not taken, strong
evidence to support an association (pharmacokinetic or
pharmacodynamic) with the outcome of interest, and be
logically and practically feasible to manage the PDDI
with available data and then be able to track the change
[2]. An expert consensus may be useful to identify the
most important DDIs from a systematic review of the
clinical literature, although this process should aim for
acceptable levels of sensitivity and specificity and pro-
vide a framework for local adaptation [1,33]. Further-
more, a critical need remains for evaluating the effects
of DDIs on patient outcomes.
With advances in clinical decision support systems
such as integration of relevant medical and laboratory
information, and national attention focused on meeting
meaningful use criteria, DDI alert programs will con-
tinue to evolve toward more electronic means for com-
munications. Even so, the same issues about the need
for careful selection and evaluation of screening criteria
apply to electronic DDI alerts. The absence of careful, in-
formed assessment of knowledge databases used for DDI
screening can lead to alerting for PDDIs that are theo-
retical, unfounded, exaggerated or erroneous [34,35]. In
addition, minimizing PDDIs is becoming more important
for PBMs and health plans in the US because Medicare is
now using quality metrics that include the incidence
of PDDIs.
There are several important limitations with this study.
Many PDDIs may not lend themselves to being assessedusing a pharmacy claims database since these data are
not useful to detect increased physician awareness and
patient monitoring, patient education, or temporarily
holding of a chronic medication. Examining changes in
claims data to measure the effect of the program may
not fully account for the full program effect as pre-
scribers may alter future prescribing after receiving an
alert. Additionally, after receiving these alerts, physicians
may have limited prescribing of future PDDIs, thereby
leading to a potential sentinel effect. In addition, special-
ists are presumably more knowledgeable about certain
therapies (e.g., dermatologists and isotretinoin-minocycline
or tetracycline or doxycycline) and these may have been
less useful PDDIs to target with a fax alert intervention.
For example, isotretinoin prescribers need to be certified to
prescribe the drug. The large number of warfarin PDDIs
may have been managed within anticoagulation clinics
with extra monitoring. Next, sample sizes for select PDDI
types were small and not all patients with PDDIs were
matched to a comparator, which reduced the sample size
and power of the statistical analysis. Also, because specific
prescribers could have received multiple fax alerts for the
same or other interactions, they may have been less re-
sponsive to the PDDI fax alert. The study was not designed
to collect the number of fax alerts received by a prescriber.
In addition, this study was “near-real time” in design and
responded when new interacting prescriptions were writ-
ten. It was unknown whether the interacting drug pair had
been previously used in the patient’s history.
It also should be noted that because the fax alert pro-
gram was near-real time, it was possible for prescribers
to intercept prescriptions before the patient picked them
up. If that was the case, then the claim would have been
reversed (or voided) and would not be captured as it ex-
amined prescription claims data. Also, pharmacies are
typically equipped with software that provides PDDI
screening and many PBMs provide soft messaging warn-
ings when claims are adjudicated. The usual clinical care
and communications that occur between prescribers and
pharmacists may have resolved the PDDI issues by other
processes not observable in the pharmacy claims data.
Conclusion
Based on the results from this fax alert analysis, there
were no significant changes in prescription medications
obtained by patients between the intervention and con-
trol prescribers. While using solely claims-based analyses
for this evaluation resulted in no detectable differences,
if PBMs elect to use fax alerts to inform clinicians about
clinically relevant PDDIs, it is likely not to have an ob-
servable impact on the claims utilization of therapeutic
alternatives. Future research should examine if pre-
scribers used other harm mitigation strategies for pa-
tients exposed to PDDIs.
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